Hormonal
Supraphysiological doses of recombinant human IGF-I (rhIGF-I) significantly improve insulin sensitivity and glycemic control in patients with type II diabetes.
This research suggests that high-dose IGF-I can drastically improve how your body uses insulin, but it is not a current standard treatment due to significant side effects like swelling and jaw pain. It serves as proof-of-concept that targeting insulin resistance directly via IGF-I pathways works, but a safer dosage needs to be found before it can be widely recommended for type II diabetes management.
In summary, IGF-I significantly lowered blood glucose as reflected by short-term and long-term indexes of glycemic control and increased insulin sensitivity.
Why this rating
Small sample size (n=12, n=9 analyzed), short duration (6 weeks), and significant side effects limit generalizability and long-term safety assessment.
Source
Recombinant Human Insulin-Like Growth Factor I Increases Insulin Sensitivity and Improves Glycemic Control in Type II Diabetes
Alan C. Moses et al. · Diabetes · 1996
DOI 10.2337/diab.45.1.91
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →